EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million Conference Call Today, May 27, 2026, at 8:30 a.m.
MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active driver of wound healing Panel supports early use of effective, less invasive
MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings support ongoing VALUE Phase III study and planned expansion into DFUs and pressure ulcers YAVNE, Israel,
MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5, 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with
EscharEx ® Phase III VALUE trial advancing as planned Expanded NexoBrid ® manufacturing facility operational; regulatory approvals expected in 2026 $17 million revenue in 2025; $54 million in cash at year-end; 2026–2028 revenue guidance reaffirmed Conference Call Today, March 5, 202 6, a t 8:30 a.
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5 th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue
MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that its management team will present at the following upcoming investor conferences:
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx ® VALUE Phase III trial in venous leg ulcers (VLUs) expected by year-end 2026; expansion to diabetic foot ulcers (DFUs) and pressure
MediWound Reports New Clinical Data Demonstrating NexoBrid ® ’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid ® removes embedded particles in friction and blast wounds, reducing pigmented wound surface by >90% Traumatic